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Abstract
AIM
To determine how the auto-antibodies (Abs) profiles 
overlap in chronic hepatitis C infection (CHC) and 
autoimmune hepatitis (AIH) and correlate to liver 
disease.
METHODS
Levels of antinuclear Ab, smooth muscle antibody (SMA) 
and liver/kidney microsomal-1 (LKM-1) Ab and markers 
of liver damage were determined in the sera of 50 
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patients with CHC infection, 20 AIH patients and 20 
healthy controls using enzyme linked immunosorbent 
assay and other immune assays. 
RESULTS
We found that AIH patients had more severe liver 
disease as determined by elevation of total IgG, 
alkaline phosphatase, total serum bilirubin and serum 
transaminases and significantly higher prevalence of 
the three non-organ-specific autoantibodies (auto-Abs) 
than CHC patients. Antinuclear Ab, SMA and LKM-1 Ab 
were also present in 36% of CHC patients and related 
to disease severity. CHC cases positive for auto-Abs 
were directly comparable to AIH in respect of most 
markers of liver damage and total IgG. These cases 
had longer disease duration compared with auto-Ab 
negative cases, but there was no difference in gender, 
age or viral load. KLM-1+ Ab CHC cases showed best 
overlap with AIH. 
CONCLUSION
Auto-Ab levels in CHC may be important markers of 
disease severity and positive cases have a disease 
similar to AIH. Auto-Abs might have a pathogenic role 
as indicated by elevated markers of liver damage. 
Future studies will unravel any novel associations 
between these two diseases, whether genetic or other.
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Core tip: This paper aims to determine what patients 
with chronic hepatitis C (CHC) and autoimmune hepatitis 
(AIH) produce autoantibodies. Disease duration in CHC 
is linked to disease severity and autoantibodies. Patients 
with severe CHC resemble AIH. 
Amin K, Rasool AH, Hattem A, Al-Karboly TAM, Taher TE, 
Bystrom J. Autoantibody profiles in autoimmune hepatitis and 
chronic hepatitis C identifies similarities in patients with severe 
disease. World J Gastroenterol 2017; 23(8): 1345-1352  Available 
from: URL: http://www.wjgnet.com/1007-9327/full/v23/i8/1345.
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INTRODUCTION
Antibodies are a vital part of the immune response 
for recognition and elimination of invading organisms. 
However, when the immune system is dysfunctional, 
it can develop antibodies that react to self. The 
development of autoantibodies (auto-Abs) generally 
occurs during auto-immune disease, but their induction 
can also be a consequence of a chronic infection in 
susceptible individuals. A number of auto-Abs with 
different specificities have been identified. As some 
auto-Abs occurrence in plasma is disease specific, 
they can be used in the diagnosis and classification of 
autoimmune diseases[1-3]. The hepatitis C virus (HCV) 
infection causes liver damage by inducing cirrhosis 
and can also lead to hepatocellular carcinoma. Recent 
studies have demonstrated that the virus may be 
involved in loss of tolerance to self-antigens and thereby 
promotion of auto-Ab production[4-6]. In particular, non-
organ-specific auto-Abs (NOSAs) including smooth 
muscle ab (SMA), anti-nuclear ab (ANA) and liver/
kidney microsomal-1 (LKM-1) ab are common and 
frequently found in sera of patients with chronic HCV 
(CHC)[7,8]. NOSA in HCV-infected patients correlate 
with the severity of necro-inflammation, fibrosis 
development, markers of liver damage: aspartate 
transaminase (AST) and alanine transaminase (ALT), 
alkaline phosphatase (AP) and levels of IgG[9].
Clinical and laboratory features of CHC can some-
times lead to a mistaken diagnosis of autoimmune 
hepatitis (AIH). AIH is characterized by a liver-specific 
autoimmune response, infiltrating immune cells, auto-
Abs in circulation, elevated immunoglobulin and serum 
transaminase level, and a favourable response to 
immunosuppression[10,11]. In AIH, ANA, SMA, and LKM-1 
Abs can differentiate the severity of the disease. The 
existence of detectable hepatitis C viral load with or 
without circulating antibodies specific to HCV can often 
be used to differentiate CHC from AIH[12]. These two 
conditions, CHC and AIH involve different management 
strategies; chronic HCV infection has until recently 
often been treated with interferon-α (IFN-α) which can 
provoke liver auto-immunity. The HCV infection can, in 
a few cases, develop into AIH, suggesting that the liver 
cells are damaged not only by the infection but also by 
an immune reaction to self[13,14]. AIH on the other hand 
requires immunosuppression, a treatment that could 
induce viral replication in cases of co-infection[11,14]. 
In this study, we have assessed the prevalence of 
ANA, SMA and LKM-1 Abs in CHC and AIH patients 
and correlated this with markers of liver disease to 
determine any overlapping features. In the study, 
disease severity, immunoglobulin levels and disease 
duration were assessed. We found that the auto-Ab 
profile was directly associated with severity of disease 
in both groups of patients and that subgroups within 
the patients showed a significant overlap in respect to 
the laboratory markers assessed. 
MATERIALS AND METHODS
A total of 70 patients and 20 healthy controls were 
recruited during the duration of this study (Table 
1). These included 50 patients diagnosed with CHC 
and 20 patients with AIH. Approval of the study was 
received from the Ethics board and the Office of the 
Vice President for Scientific Affairs and Postgraduate 
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Studies at the Sulimani University. CHC patients 
were diagnosed based on anti-HCV antibody po-
sitivity and by assessment of their HCV RNA viral 
load. Patients with liver damage due to excessive 
alcohol consumption, hepatotoxic drugs, or human 
immunodeficiency virus infections were excluded from 
the study. Patients diagnosed positive for hepatitis 
B surface antigen were also excluded. The diagnosis 
of AIH was based on the criteria established by the 
international AIH group. This includes predominant 
elevation of serum aminotransferase and IgG, exclusion 
of viral hepatitis, toxic or alcoholic liver injury and 
with a liver biopsy confirming lymphocyte infiltration 
indicative of autoimmune disease[15]. Some patients 
were diagnosed for the first time when enrolled in the 
study while others had been undergoing treatment for 
between two and 11 years. Information of age and 
gender was recorded for each patient. Twenty healthy 
gender- and age-matched blood donors served as 
controls. 
Enzyme linked immunosorbent assay and other assays
SMA, ANA and LKM-1 Ab in serum were assayed 
by enzyme linked immunosorbent assay (ELISA) 
according to the manufacturer’s instructions (CUSABIO, 
Wuhan, China). Total IgG and IgM was estimated 
quantitatively using a biochemical assay according to 
the manufacturer’s instructions (VITAL Diagnostics, 
Puteaux, France). Serum AP, ALT, AST, serum albumin 
and total serum bilirubin (TSB) was quantitatively 
determined using a biochemical assay (BIOLABO, 
Maizy, France).
Statistical analysis
Analysis of data was performed by using software 
package SPSS (Statistical Package for Social Science) 
version 21. Normal distribution of the data was 
determined using D’Agostino & Pearson omnibus 
normality test. Results are expressed as mean ± SD. 
Statistical differences were determined by Duncan’s 
test for multiple comparisons after analysis of variance. 
Significant differences between groups were determined 
using the χ2 test. A P value less than 0.05, 0.01 or 0.001 
respectively, were considered statistically significant at 
the different levels.
RESULTS
In the aim of discovering overlapping features com-
paring CHC and AIH cases such patients were recruited 
and sera gathered for analysis of auto-Ab levels and 
levels of markers of liver damage. Table 1 shows the 
demographics of the CHC-, the AIH- and the healthy 
control-group (HC). The CHC group included 50 pa-
tients (48% female) and the mean age were 33.4 ± 
2.4 years. In agreement with other studies, AIH was 
more common among females (gender ratio 3:1) with 
males being older when diagnosed (47.0 ± 3.1 years). 
There were no significant differences in age or gender 
comparing patients and HC.
One or more of the auto-Abs was detected in 36% 
of CHC patients’ serum (9 male, 9 female, Table 2). 
Reactivity for ANA was the most frequent (32%, 7 
male, 9 female) while LKM-1 Ab was detectable in 
22% (4 male, 7 female) and SMA in 8% (1 male, 3 
female) of the cases. Also 20% of the healthy controls 
were positive for ANA (2 male, 2 female) but not for 
LKM-1 or SMA. A statistical analysis using the Chi-
square test showed that there was no significant 
difference in the level of ANA comparing the control 
group and the CHC group. In AIH patients, 75% (3 
male, 12 female) had at least one type of auto-Ab. 
ANA was also the most frequently detected, 65% (3 
male, 10 female). LKM-1 Ab was identified in 9 cases 
(45%) all of which were female. SMA was not detected 
in any of the AIH patient’s serum. A statistical analysis 
showed significant differences between the AIH and 
CHC groups of patients regarding auto-Ab prevalence 
(AIH patients were more often positive for the auto-
Abs, P = 0.0031, Table 2). The level of ANA and 
LKM-1, however, tended to be highest in CHC patients 
plasma (for ANA level in CHC: 4.6 ± 2.7 pg/mL and in 
AIH, 3.3 ± 1.8 pg/mL, for LKM-1, level in CHC: 4.9 ± 
2.8 and in AIH: 4.0 ± 1.4 pg/mL). 
Next, we assessed the level of IgG in the patients’ 
serum. As expected, the highest level was found in 
the serum from the AIH patients (Table 3). There was 
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Table 1  Distribution of study group according to age and 
gender
Parameter CHC (n  = 50) AIH (n  = 20) HC (n  = 20)
Age (yr), mean ± SD 
Range 10-65 16-69 16-69
mean ± SD 33 ± 2.38 37 ± 3.22 37 ± 3.22
Gender, n (%)
   Female 24 (48) 15 (75) 15 (75)
   Male 26 (52) 5 (25) 5 (25)
Age (yr), mean ± SD
   Female 34 ± 2.28 35 ± 3.42 35 ± 3.42
   Male 33 ± 2.38 47 ± 3.12 47 ± 3.12
CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; HC: Hepatitis 
virus.
Table 2  Distribution and comparison of autoantibodies 
between the chronic hepatitis C and the autoimmune hepatitis 
patient group n  (%)
Autoantibodies CHC AIH HC HCV-AIH
(n  = 50) (n  = 20) (n  = 20) P  value
SMA 4 (8) 0 (0) 0 (0)
LKM-1 11 (22)   9 (45) 0 (0)
ANA 16 (32) 13 (65)   4 (20)
Total 31 (36) 23 (75)   4 (20) 0.00311
1Indicates significant difference on the 0.01 level. Statistically significant 
differences were determined using analysis of variance followed by 
Duncan’s test. CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; 
HC: Hepatitis virus;  HCV: Hepatitis C virus.
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was the concentration of IgM (Table 7). 
DISCUSSION
In this study, we have shown that certain patients with 
chronic hepatitis C (CHC) infection develop an auto-
Ab profile similar to that of AIH. This group of patients 
had longer disease duration and more extensive liver 
damage, thereby sharing many features of AIH. The 
comparison of LKM-1 Ab positive patient emphasised 
the similarity between severe cases of CHC and the 
AIH group. Only IgM levels discriminated these two 
groups of patients. Such knowledge is important when 
interpreting biomarker results from patients with 
liver disease. Furthermore, the findings suggest an 
underlying similarity in disease aetiology in these cases 
of auto-Ab positive CHC and AIH patients.
It is important to differentiate between CHC and 
AIH as their treatment is completely different[18]. Thus 
although auto-Abs and elevated liver enzymes might 
suggest a diagnosis of AIH, patients require further 
investigation to exclude CHC. When comparing NOSA 
production from the CHC and AIH patients in our study 
there was a significant difference, underscoring the 
overall more severe progression of the disease in the 
patients with autoimmune disease. In other studies 
of CHC 6%-41% was positive for ANA, 5%-66% for 
SMA, and up to 86% for LKM-1 Abs[12,19-22]. There are 
several reasons to explain why such a variation in 
levels of auto-Abs has been observed. ANA measured 
by indirect immune-fluorescence of Hep-2 cells or by 
different ELISAs produce variable results dependent on 
the method used[23]. Regional differences in prevalence 
of autoimmune manifestations in HCV might influence 
the results[5,24]. Furthermore, differences in auto-Ab 
levels might be due to the local ethnic background. 
Hence, in HCV infected patients from Crete or Sweden, 
very few showed positivity for LKM-1[25,26]. 
It is not known why 36% of the CHC infected 
patients in our study develop auto-Abs. Liver damage 
in CHC cases results in release of auto-antigens to 
which the immune system can react[27]. As stated 
above, infection duration might be one factor in 
the development of auto-Abs. Other studies have, 
however, failed to identify an association between 
infection duration and NOSA levels[9,28]. Other factors 
such as presence of the HLR-DR3 genotype might be 
more important for auto-Ab development[29].
AIH is known to induce liver damage[11]. CHC 
patients with auto-Abs and long-standing disease 
had liver damage at the same level as the AIH cases. 
The appearance of auto-Ab positive CHC patients can 
show such high similarity to AIH that they can be 
misdiagnosed. This is especially the case for patients 
with extrahepatic symptoms[10,11]. The presence of 
circulating antibodies specific to HCV is chief for correct 
diagnosis[12]. The liver damage experienced during AIH 
is induced by infiltrated inflammatory cells which can 
no significant difference in IgG level comparing CHC 
and AIH, but the levels were significantly higher than 
the healthy controls (Table 3). In contrast, although 
significantly higher than the healthy controls, the 
mean concentration of IgM remained within the normal 
range in the CHC and AIH groups. The AIH patients 
IgM level was significantly higher than the CHCs’ and 
the HCs’.
All of the markers of liver damage (AP, ALT AST, 
and TSB) except serum albumin assessed in the serum 
were elevated above the level of the HC’s for both the 
AIH patients and the CHC patients (Table 4). However, 
in the AIH group, the levels of these markers were 
significantly higher than in the CHC group (Duncan’s 
test, P < 0.05). Only the level of TSB was at a similar 
level in both patient groups. 
To determine whether the presence of auto-Abs 
in the CHC group was associated with worse disease 
progression we compared the level of liver damage 
markers from patients with and without auto-Abs. 
We found that the duration of infection was twice as 
long for patients with auto-Abs compared to without. 
Furthermore, patients with auto-Abs had significantly 
higher levels of IgG, AP, AST, ALT and TSB (Table 5). 
This finding is in agreement with that of a previous 
study[9]. The age and gender of the patients, viral load, 
IgM, and serum albumin did, however, not differ in the 
two CHC subgroups.
The CHC patients with auto-Abs, the longest 
duration of infection and the highest level of markers 
of liver damage were directly comparable with the AIH 
patients (Table 5). These two groups were remarkably 
similar in respect to IgG levels and most markers of 
liver injury (Table 6). Only the levels of IgM and TSB 
were higher in the AIH patients (P < 0.05).
Further, we found that the LKM-1 Abs present only 
in sera of female patients in the AIH group. LKM-1 
Ab positive AIH patients are often young females 
with worse prognosis[16,17]. In our study, 22% of the 
CHC patients were positive for LKM-1 Ab. However, 
such positivity was found among both male and 
female subjects (5 male, 6 female). Importantly, our 
immunological and biochemical analysis revealed that 
there were no significant differences between these 
two subgroups of LKM-1+ CHC and AIH in respect of 
IgG, AP, AST, ALT, albumin or TSB. The only difference 
Table 3  Estimation of IgG and IgM and comparison between 
study groups (mean ± SD)
Groups IgG (mg/dL) IgM (mg/dL)
CHC 1841 ± 66.44 176 ± 5.561
AIH   2054 ± 152.62 228 ± 5.561
HC  1098 ± 57.691 127 ± 4.801
1Denotes significant difference comparing with the other two groups, P < 
0.05. Statistically significant differences were determined using analysis 
of variance followed by Duncan’s test. CHC: Chronic hepatitis C; AIH: 
Autoimmune hepatitis; HC: Hepatitis virus.
Amin K et al . Autoantibodies in CHC and AIH
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be visualized by a liver biopsy[11]. Indeed a liver biopsy 
is necessary for confirmation of AIH. Immune cells are, 
however, present in the liver albeit to a lesser extent 
also in CHC patients with serum auto-antibodies[30]. 
We speculate that the severe disease seen in AIH and 
CHC with auto-Abs is mediated by similar mechanisms 
and that the auto-Abs can contribute to liver damage 
in these cases. 
Sixty-five percent of the AIH patients had any 
of the three auto-Abs investigated in this study. As 
previously reported, ANA was the most prevalent 
auto-Ab[9]. LKM-1 Ab is a serological marker for one 
subtype of the autoimmune disease, AIH-2 which is 
more prevalent among adolescent women and young 
girls[16,17]. In this study LKM-1 Ab was detected in 45% 
of samples which is an unusually high proportion. 
This might be explained by that the study contained 
many young women. It is also possible that the 
genotype associated with the development of LKM-1 
antibodies is more prevalent in the area from where 
patients were recruited[31]. LKM-1 has been shown to 
recognize CYP2D7 which is expressed on the surface of 
hepatocytes. Such self-recognition, unique for LKM-1 
among NOSA, could explain the worse disease in these 
patients[32]. Possibly of importance, epitopes within 
CYP2D7 share homology with HCV proteins[33]. CYP2D6 
epitopes can induce both poly-reactive B cells and T 
cells[34]. It has been proposed that polymorphisms in 
the CYP2D6 gene lead to altered amino acids sequences 
and more immunogenic epitopes[35]. It is not known 
whether CYP2D6 polymorphisms could differentiate 
Table 5  Comparison of different parameters in chronic 
hepatitis C with and without autoantibodies (mean ± SD)
Parameters CHC with CHC without P  value
autoantibodies autoantibodies
M/F (9/9) M/F (17/15)
Mean age (yr)   33 ± 16      34 ± 14.3   0.36 NS
Viral load 
(copy/mL)
    8.3 × 105 ± 10.4 × 106     3 × 106 ± 19 × 105   0.52 NS
Duration of 
infection (mo)
  21.3 ± 12.3    11 ± 7.3 0.0022
IgG (mg/dL)    2109 ± 462.4 1630 ± 323 0.0011
IgM (mg/dL) 190 ± 25    172 ± 45.3 0.3 NS
AP (U/L)    428 ± 91.5   221 ± 104 0.0011
AST (U/L)      52 ± 12.7      41 ± 9.81 0.0071
ALT (U/L)    36 ± 9.7    27 ± 7.2 0.0071
S. Albumin 
(g/dL)
    3.8 ± 0.87     3.9 ± 0.72   0.47 NS
TSB (mg/dL)   1.5 ± 3.1     0.8 ± 0.58 0.0011
1,2Indicate significant difference on the 0.01 and the 0.001 level respectively, 
NS indicates non-significance. Statistically significant differences were 
determined using analysis of variance followed by Duncan’s test. 
CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; AP: Alkaline 
phosphatase; AST: Aspartate transaminase; TSB: Total serum bilirubin; 
ALT: Alanine transaminase.
Table 6  Autoantibody positive chronic hepatitis C and 
autoimmune hepatitis, comparison of different parameters 
(mean ± SD)
Parameters Autoantibody 
positive CHC 
(n  = 18)
Autoantibody 
positive AIH 
(n  = 20)
P  value
IgG (mg/dL) 2109 ± 249  2053 ± 710.5 0.42 NS
IgM (mg/dL)    190 ± 26.8  227 ± 63.1 0.0271
AP (U/L)    428 ± 37.9    373 ± 166.1 0.33 NS
AST (U/L)      52 ± 8.42      57 ± 18.64 0.42 NS
ALT (U/L)    36 ± 5.5    37 ± 15.6 0.81 NS
TSB (mg/dL)   1.5 ± 4.1 4.0 ± 7.0   0.00332
Albumin (g/L)     3.8 ± 0.78   3.3 ± 0.69 0.12 NS
1,2Indicate significant difference on the 0.05 and the 0.01 level respectively, 
NS indicates non-significance. Statistically significant differences were 
determined using analysis of variance followed by Duncan’s test. 
CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; AP: Alkaline 
phosphatase; AST: Aspartate transaminase; TSB: Total serum bilirubin; 
ALT: Alanine transaminase.
Table 7  Comparison between liver/kidney microsomal-1 
positive patients in chronic hepatitis C and autoimmune 
hepatitis groups (mean ± SD)
Parameters Groups P  value
LKM-1+ in AIH LKM-1+ in CHC
M/F (0/9) M/F (5/6)
Mean age (yr) 31 ± 10     35 ± 19   0.51 NS
IgG (mg/dL)  2205 ± 566.1      2522 ± 295.6   0.34 NS
IgM (mg/dL)    262 ± 41.21        185 ± 26.26 0.0011
AP (U/mL)    404 ± 146.7 472 ± 3   0.57 NS
AST (U/mL)      64 ± 12.71          57 ± 37.92   0.22 NS
ALT (U/mL)    41 ± 9.64        40 ± 5.41   0.45 NS
S. Albumin (g/dL) 3.4 ± 0.8     3.9 ± 0.9 0.5 NS
TSB (mg/dL)   3.4 ± 4.97       1.9 ± 3.90   0.06 NS
1Indicates significant difference on the 0.01 level, NS indicates non-
significance. Statistically significant differences were determined using 
analysis of variance followed by Duncan’s test. CHC: Chronic hepatitis C; 
AIH: Autoimmune hepatitis; AP: Alkaline phosphatase; AST: Aspartate 
transaminase; TSB: Total serum bilirubin; ALT: Alanine transaminase; 
LKM-1: Liver/kidney microsomal-1.
Table 4  Comparison of the markers of liver injury among study groups (mean ± SD)
Groups AP (UI/L) ALT (UI/L) AST (UI/L) ALB (g/dL) TSB (mg/dL)
CHC   296 ± 19.901 30 ± 1.321 45 ± 1.711 3.8 ± 0.112 1.0 ± 0.272
AIH   373 ± 32.101 37 ± 3.201 56 ± 4.101 3.3 ± 0.151 4.0 ± 1.571
HC 171 ± 8.301 19 ± 1.001 28 ± 1.281 4.0 ± 0.062 0.6 ± 0.052
1Denotes significant difference comparing with the other two groups, P < 0.05; 2Indicate significant difference comparing with the group indicated with 
an 1only. Statistically significant differences were determined using analysis of variance followed by Duncan’s test. CHC: Chronic hepatitis C; AIH: 
Autoimmune hepatitis; HC: Hepatitis virus; ALB: Albumin; AP: Alkaline phosphatase; AST: Aspartate transaminase; TSB: Total serum bilirubin; ALT: 
Alanine transaminase. 
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AIH-1 and AIH-2. There are, however, other diffe-
rences between the AIH subtypes; AIH-2 share an 
antibody profile with autoimmune polyendocrine 
syndrome type 1 which is caused by a mutation in the 
AIRE gene, leading to a break in tolerance[31]. In this 
study the levels of both ANA and LKM-1 tended to be 
higher in CHC than in AIH. Other studies have detected 
higher level of LKM-1 in AIH-2, than in CHC[36]. Further 
studies are required to explain why LKM-1 and ANA is 
higher in sera from the CHC patients than from AIH 
patients in this study. High level of LKM-1 Ab in CHC 
has previously been reported in paediatric cohorts[37]. 
Similar to our findings, LKM-1 Ab have previously 
been reported in HCV where the titre is associated 
with disease severity[38]. It is not known whether there 
is any relationship between patients with CHC, AIH 
and LKM-1 Ab or whether these CHC cases are more 
prone to develop AIH. Although no longer commonly 
used, it has been proposed that IFNα therapy for 
CHC, can induce autoimmune symptoms in LKM-1+ 
individuals[39]. 
SMA was detected in none of the patients in the 
AIH group, which is in disagreement with previous 
studies. As many as 70% to 80% of AIH cases have 
been described as SMA positive[40]. The successful 
treatment of our patients might be one explanation for 
the lack of SMA+ patients as this is this is associated 
with the disappearance of serum ANA and SMA[41]. 
It should be pointed out that seronegativity in AIH 
have been described in 1%-34% of cases (in our 
study 25%) underscoring the heterogeneity of this 
autoimmune disease[42]. 
High IgG levels are a distinctive feature of AIH[43-45]. 
In our study, however, there was no significant diffe-
rence in levels comparing AIH and CHC. Other studies 
have reported elevated levels of IgG in both AIH and 
CHC patients[38]. The level of IgG has previously been 
associated with severity of disease among chronic 
HCV infected patients which is in line with our findings. 
Both diseases are characterized by activation of B cells 
and a large number of plasma cells[6]. We speculate 
that many of these released auto-Abs are of the 
IgG subclass which can explain the elevated level of 
these Abs in serum from both patient groups. This 
polyclonal activation is likely taking place either as a 
consequence of chronic antigen stimulation or due to 
loss of immune regulation[46,47]. Our interest is in Th17 
cells that have an established pathogenic function in 
autoimmune diseases[48]. Th17 cells are present in the 
liver of both AIH and CHC patients[30]. Further studies 
will determine whether these cells could contribute 
to B cell activation or generation of an inflammatory 
environment that promotes auto-Ab production[49,50]. 
In conclusion, we found AIH-related auto-Abs 
associated with HCV infection. The emergence of auto-
Abs in CHC might be infection duration dependent, 
but it is not related to gender, the age of patients and 
serum viral load. Auto-Abs, especially LKM-1, in CHC 
cases might have pathogenic role leading to more 
severe disease which is indicated by an alteration 
of liver function tests and elevation of total IgG. It 
is not known whether auto-Ab prevalence is due to 
prolonged disease or whether certain patients are 
more susceptible for their development. We conclude 
that auto-Ab levels in CHC may be important markers 
of disease severity and that these patients have a 
disease similar to AIH. Future studies will unravel 
any further associations between these two diseases, 
whether genetic or other.
COMMENTS
Background
Worldwide, 130-200 million individuals are infected with hepatitis C. Although 
current therapies control the disease rather well, 80% of the infected patients 
develop chronic hepatitis C (CHC). It is not known why some of the patients 
develop more severe disease. Autoimmune hepatitis (AIH) is a disease of the 
liver that has a prevalence of 10-20/100000 individuals. This disease can be 
controlled by using immunosuppressive therapies. In this paper the authors 
show that the presence of non-organ specific autoantibodies (NOSA) in both 
CHC and AIH is associated with severe disease. Although overall CHC is less 
damaging to the liver than AIH cases, a subgroup can be defined with more 
severe pathology. This CHC subgroup is defined by liver/kidney microsomal-1 
(LKM-1) positivity. 
Research frontiers
In the field of autoimmunity, novel therapies have recently been developed as 
well as better understanding of the aetiology of disease. Recent discoveries of 
novel immune cells and their dysregulation in the autoimmunity have increased 
the knowledge of disease aetiology and provided prospect for development of 
novel therapies. Novel genome-, transcriptome- and epigenome-sequencing 
techniques have given important insight of autoimmune associations to certain 
genomic regions genomic and the immunological heterogeneity underlying 
disease. As some subpopulations of CHC patients have antibodies that react 
to self, we speculate that the analysis of novel immune cells and comparison of 
immune cells from CHC patients with AIH using novel genomic and epigenomic 
tools can provide disease related knowledge useful for novel future treatment-
strategies of these patients. 
Innovations and breakthroughs
Th17 cells have recently been implicated in the development of AIH and 
response to hepatitis C virus infection in the liver. Although it is not known how 
these cells confer pathology, studies from other autoimmune diseases has 
suggested that the cells support B cell germinal centre formation and production 
of auto-antibodies. This can be both through IL-21 production by Th17 cells 
and through transdifferentiation of Th17 cells to follicular T cells. Studies have 
shown that polymorphisms in the TNFα gene are associated with development 
of AIH. We are currently analysing how TNFα is suppressing Th17 cell 
expansion in rheumatoid arthritis patients. Future studies by authors would aim 
to determine the role of Th17 cells and possibly TNFα in the development of 
autoantibodies (auto-Abs) in AIH and LKM-1+ CHC.
Applications
The current study has characterized the immune response in CHC and AIH 
in homogenous patient cohorts. The findings differentiated CHC and AIH 
patients into different subgroups. These findings open the way for future 
studies of immune cell mediated induction of autoimmunity in CHC and AIH. 
We aim to characterize immune cells present in the liver and the peripheral 
blood of the patient cohorts. Further, genome wide association studies, 
analysis for expression quantitative trait loci and whole genome epigenome 
will be undertaken to gain better understanding of the autoimmune disease 
process which is regulating the immune cells. Findings from these studies 
will be correlated to disease severity, auto-Ab levels and other markers of 
liver disease. Importantly the knowledge gained will provide the possibility 
to discover overlapping genomic/epigenomic features between AIH and the 
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subgroup of LKM-1 positive CHC patients with severe disease.
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The manuscript by Amin et al compares the incidence of auto-Abs associated 
with AIH, immunoglobulin levels and markers of liver disease in groups of 
age-matched subjects with autoimmune hepatitis, CHC infection and healthy 
controls.
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